Dapagliflozin/saxagliptin - AstraZeneca

Drug Profile

Dapagliflozin/saxagliptin - AstraZeneca

Alternative Names: Qtern; Saxa/dapa; SaxaDapa; SaxaDapa FDC; Saxagliptin/dapagliflozin

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca
  • Class Adamantanes; Antihyperglycaemics; Chlorobenzenes; Cycloparaffins; Dipeptides; Glucosides; Nitriles; Organic bridged compounds; Piperidines; Pyrans; Small molecules
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 27 Apr 2018 Regulatory submission withdrawn for Type-2 diabetes mellitus (Adjunctive treatment) in European Union (PO)
  • 27 Mar 2018 Preregistration for Type-2 diabetes mellitus (Adjunctive treatment) in European Union (PO) before March 2018
  • 11 Sep 2017 Safety and efficacy data from a phase III trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top